Don’t give in to big pharma on drug pricing | Letters
PositiveFinancial Markets

In a recent letter, Simon Dixon argues that while drug manufacturers like Eli Lilly may criticize the UK's drug pricing, the NHS should actually celebrate these prices. This perspective highlights the importance of affordable medication for public health and the sustainability of the NHS, emphasizing that the current pricing system benefits patients and the healthcare system as a whole.
— Curated by the World Pulse Now AI Editorial System